Plasma exchange in early kidney graft rejection associated with anti-donor antibodies.
Patients with early rejection of kidney allografts associated with anti-donor antibodies have been randomized in two groups which received, respectively, either the conventional corticosteroid/azathioprine treatment or extensive plasma exchanges (PE) plus the conventional treatment. Data on the monitoring of anti-T or anti-B donor lymphocytes, as well as anti-panel or autoreactive cytotoxicity are described. Although the titer of anti-donor antibodies is decreased in the PE-treated group there is no sustained improvement of graft function compared to the control group. Thus, in these stereotyped rejection episodes, which are likely to be antibody mediated, there is no significant effect of extensive and early plasma exchange.
D000906:Antibodies / Q000276:immunology; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D006084:Graft Rejection; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use; D010951:Plasma Exchange; D011897:Random Allocation; D013997:Time Factors; D014019:Tissue Donors
D000906:Antibodies; D000961:Antilymphocyte Serum; D001379:Azathioprine; D008775:Methylprednisolone